Suppr超能文献

治疗 65 岁以上患者的垂体功能减退症:临床研究综述。

Treating Hypopituitarism in the Over 65s: Review of Clinical Studies.

机构信息

Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Unicamillus-Saint Camillus International University of Health Sciences, Rome, Italy.

出版信息

Clin Interv Aging. 2023 Mar 21;18:423-439. doi: 10.2147/CIA.S370782. eCollection 2023.

Abstract

The current increase of life expectancy is associated with the presence of endocrine diseases in the elderly. The management of hypopituitarism in this group of patients is a challenging task. A correct diagnosis, which represents an essential requisite for an appropriate medical treatment, can be difficult because of the physiological changes occurring in pituitary function with aging, which may lead to challenges in the interpretation of laboratory results. Furthermore, the treatment requires several careful considerations: the need to restore the hormonal physiology with replacement therapies must be balanced with the need to avoid the risks of the over-replacement, especially in the presence of concomitant cardiovascular and metabolic disease. Interactions with other drugs able to modify the absorption and/or the metabolism of hormonal replacement therapies should be considered, in particular for the treatment of hypoadrenalism and hypothyroidism. The most important challenges stem from the lack of specific studies focused on the management of hypopituitarism in older people.

摘要

目前预期寿命的延长与老年人内分泌疾病的存在有关。管理这组患者的垂体功能减退症是一项具有挑战性的任务。正确的诊断,这是适当治疗的必要条件,由于垂体功能随年龄增长而发生的生理变化,可能导致实验室结果的解释出现困难。此外,治疗需要仔细考虑几个方面:需要用替代疗法恢复激素生理学,必须与避免过度替代的风险相平衡,特别是在存在心血管和代谢疾病的情况下。应考虑与其他能够改变激素替代疗法吸收和/或代谢的药物相互作用,特别是治疗肾上腺功能减退和甲状腺功能减退症。最重要的挑战源于缺乏针对老年人垂体功能减退症管理的具体研究。

相似文献

1
Treating Hypopituitarism in the Over 65s: Review of Clinical Studies.
Clin Interv Aging. 2023 Mar 21;18:423-439. doi: 10.2147/CIA.S370782. eCollection 2023.
2
Diagnosing and treating the elderly individual with hypopituitarism.
Rev Endocr Metab Disord. 2024 Jun;25(3):575-597. doi: 10.1007/s11154-023-09870-w. Epub 2023 Dec 27.
3
GH Deficiency and Replacement Therapy in Hypopituitarism: Insight Into the Relationships With Other Hypothalamic-Pituitary Axes.
Front Endocrinol (Lausanne). 2021 Oct 19;12:678778. doi: 10.3389/fendo.2021.678778. eCollection 2021.
4
Hypopituitarism.
Pituitary. 2006;9(4):335-42. doi: 10.1007/s11102-006-0416-5.
5
Hypopituitarism and anemia: effect of replacement therapy with hydrocortisone and/or levothyroxine.
J Endocrinol Invest. 2005 Jun;28(6):528-33. doi: 10.1007/BF03347241.
6
Management of hypopituitarism: a perspective from the Brazilian Society of Endocrinology and Metabolism.
Arch Endocrinol Metab. 2021 Nov 1;65(2):212-230. doi: 10.20945/2359-3997000000335. Epub 2021 Feb 24.
7
Growth hormone replacement improved oocyte quality in a patient with hypopituitarism: A study of follicular fluid.
Ann Endocrinol (Paris). 2021 Dec;82(6):590-596. doi: 10.1016/j.ando.2021.05.003. Epub 2021 Jun 27.
8
Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
Clin Endocrinol (Oxf). 2007 Jan;66(1):72-7. doi: 10.1111/j.1365-2265.2006.02688.x.
9
Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
Growth Horm IGF Res. 2004 Jun;14 Suppl A:S51-8. doi: 10.1016/j.ghir.2004.03.013.
10
Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment.
Front Endocrinol (Lausanne). 2021 Mar 15;12:634415. doi: 10.3389/fendo.2021.634415. eCollection 2021.

引用本文的文献

1
Diagnosing and treating the elderly individual with hypopituitarism.
Rev Endocr Metab Disord. 2024 Jun;25(3):575-597. doi: 10.1007/s11154-023-09870-w. Epub 2023 Dec 27.

本文引用的文献

1
Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.
J Endocrinol Invest. 2023 Mar;46(3):587-597. doi: 10.1007/s40618-022-01940-1. Epub 2022 Oct 17.
2
A Multicenter Cohort Study in Patients With Primary Empty Sella: Hormonal and Neuroradiological Features Over a Long Follow-Up.
Front Endocrinol (Lausanne). 2022 Jun 23;13:925378. doi: 10.3389/fendo.2022.925378. eCollection 2022.
3
Opioids and pituitary function: expert opinion.
Pituitary. 2022 Feb;25(1):52-63. doi: 10.1007/s11102-021-01202-y. Epub 2022 Jan 23.
5
Speed of response to dopaminergic agents in prolactinomas.
Endocrine. 2022 Mar;75(3):883-888. doi: 10.1007/s12020-021-02953-1. Epub 2021 Nov 30.
6
Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients.
Growth Horm IGF Res. 2022 Feb;62:101440. doi: 10.1016/j.ghir.2021.101440. Epub 2021 Nov 17.
7
Should patients with adult GH deficiency receive GH replacement?
Eur J Endocrinol. 2021 Nov 30;186(1):D1-D15. doi: 10.1530/EJE-21-0534.
9
Glucocorticoid induced adrenal insufficiency.
BMJ. 2021 Jul 12;374:n1380. doi: 10.1136/bmj.n1380.
10
GH Replacement in the Elderly: Is It Worth It?
Front Endocrinol (Lausanne). 2021 Jun 15;12:680579. doi: 10.3389/fendo.2021.680579. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验